Medtronic PLC (MDT) Shares Bought by Carroll Financial Associates Inc.

Carroll Financial Associates Inc. increased its holdings in Medtronic PLC (NYSE:MDT) by 0.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,154 shares of the medical technology company’s stock after acquiring an additional 141 shares during the quarter. Carroll Financial Associates Inc.’s holdings in Medtronic were worth $1,562,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also made changes to their positions in MDT. TIAA CREF Investment Management LLC raised its holdings in Medtronic by 2.7% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 4,143,519 shares of the medical technology company’s stock worth $407,598,000 after acquiring an additional 110,169 shares during the period. Nordea Investment Management AB bought a new position in Medtronic in the 3rd quarter worth $738,453,000. Kepos Capital LP raised its holdings in Medtronic by 76.0% in the 3rd quarter. Kepos Capital LP now owns 66,530 shares of the medical technology company’s stock worth $6,545,000 after acquiring an additional 28,720 shares during the period. Legal & General Group Plc raised its holdings in Medtronic by 1.5% in the 3rd quarter. Legal & General Group Plc now owns 6,926,159 shares of the medical technology company’s stock worth $681,146,000 after acquiring an additional 101,574 shares during the period. Finally, WealthPLAN Partners LLC raised its holdings in Medtronic by 3.3% in the 3rd quarter. WealthPLAN Partners LLC now owns 33,467 shares of the medical technology company’s stock worth $3,085,000 after acquiring an additional 1,060 shares during the period. 81.50% of the stock is owned by institutional investors.

NYSE:MDT opened at $84.22 on Monday. Medtronic PLC has a 52-week low of $78.29 and a 52-week high of $100.15. The company has a current ratio of 2.36, a quick ratio of 1.92 and a debt-to-equity ratio of 0.47. The stock has a market cap of $112.95 billion, a PE ratio of 17.66, a P/E/G ratio of 2.21 and a beta of 0.81.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 19th. The medical technology company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.05. Medtronic had a net margin of 16.10% and a return on equity of 13.85%. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.53 billion. During the same quarter in the previous year, the firm posted $1.17 EPS. The business’s revenue was up 2.4% compared to the same quarter last year. On average, research analysts expect that Medtronic PLC will post 5.15 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 12th. Stockholders of record on Friday, March 22nd were issued a dividend of $0.50 per share. The ex-dividend date of this dividend was Thursday, March 21st. This represents a $2.00 annualized dividend and a dividend yield of 2.37%. Medtronic’s payout ratio is 41.93%.

Several brokerages recently commented on MDT. Morgan Stanley lifted their target price on shares of Medtronic from $98.00 to $102.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 2nd. Needham & Company LLC reiterated a “strong-buy” rating and issued a $117.00 target price (down previously from $120.00) on shares of Medtronic in a report on Monday, February 4th. Northland Securities reiterated a “hold” rating and issued a $84.00 target price on shares of Medtronic in a report on Monday, March 18th. BTIG Research upgraded shares of Medtronic from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a report on Tuesday, January 15th. Finally, Citigroup downgraded shares of Medtronic from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $109.00 to $96.00 in a report on Wednesday, January 2nd. Ten equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Medtronic has an average rating of “Buy” and a consensus price target of $103.39.

COPYRIGHT VIOLATION NOTICE: “Medtronic PLC (MDT) Shares Bought by Carroll Financial Associates Inc.” was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/04/22/medtronic-plc-mdt-shares-bought-by-carroll-financial-associates-inc.html.

Medtronic Company Profile

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Featured Story: Do You Need a Fiduciary?

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.